We evaluated the low affinity neurotrophin receptor (p75 NTR ) as a marker of breast myoepithelial cells. Immunohistochemical staining for p75 NTR was performed on paraffin sections of 122 malignant breast lesions, 28 benign lesions and the adjacent normal breast tissue. The staining pattern was compared to those of myosin heavy chain and p63. p75
The presence of myoepithelial cells in a breast lesion is used as a criterion to distinguish invasive mammary carcinoma from carcinoma in situ or from sclerosing benign breast lesions. However, this distinction is sometimes difficult to be made on hematoxylin-eosin-stained sections, and it often requires immunohistochemical visualization of the myoepithelial cells. A variety of myoepithelial markers have been used for this purpose including several smooth muscle-associated proteins, 1,2 cytokeratin subtypes, 3, 4 S-100 protein, 5, 6 CD10, 7 maspin, 8 and p63. 9, 10 The immunohistochemical studies have shown that the interpretation of myoepithelial markers can be complicated by their crossreactivity with the stromal compartment of mammary gland or luminal/tumor cells. We believe that these difficulties can be overcome by the use of a combination of carefully selected complementary myoepithelial markers. Neurotrophins (nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, neurotrophin-4/5) play critical roles in the development, maintenance, survival, and apoptosis of the nervous system. 11 In addition, they also elicit a wide range of responses in certain non-neural tissues. 12 Neurotrophins' effects are initiated by interactions with specific receptors with low or high affinity (Huang et al 11 and references herein). p75 NTR is a transmembrane glycoprotein member of the TNF-receptor superfamily. It binds with low affinity all of the neurotrophins and can mediate cellular survival or apoptosis directly or indirectly through interaction with the high affinity neurothrophin receptors (Trks). p75
NTR is expressed in neural as well as in non-neural tissues including breast myoepithelial cells. 13, 14 However, its diagnostic utility as a marker of breast myoepithelial cells has not been evaluated. Here we examine p75 NTR expression in benign and malignant breast lesions and compare its expression pattern with those of well-established myoepithelial markers such as p63 and myosin heavy chain.
Materials and methods

Tissues
Immunohistochemical staining for p75
NTR was performed on paraffin sections of 64 invasive ductal carcinomas, 11 invasive lobular carcinomas, 10 tubular carcinomas, six invasive papillary carcinomas, four mucinous carcinomas, two medullary carcinomas, three metaplastic carcinomas (two spindle cell carcinomas and one matrix producing carcinoma), 18 ductal carcinomas in situ, two lobular carcinomas in situ, two noninvasive papillary carcinoma, eight intraductal papillomas, six usual ductal hyperplasias, six specimens with sclerosing adenosis, two specimens with fibroadenomatoid change, and six fibroadenomas. The adjacent normal breast tissue was also studied. Sixty-four of the invasive carcinomas and seven of the in situ carcinomas were included in a tissue microarray. Two different areas from those tumors were sampled.
Immunohistochemical Analysis
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded sections by using an automatic immunostainer (Ventana Medical System Inc., Tucson, AZ, USA) and a streptavidinbiotin-peroxidase complex technique (LSAB2 system, DAKO, Carpinteria, CA, USA). Heat-induced epitope retrieval was performed in a Handy Steamer Plus (Black and Decker, Shelton, CT) in citrate buffer, pH 6.0 (DAKO) for 20 min. The following primary antibodies were used: anti-p75 NTR (clone ME20.4; dilution 1:100; Santa Cruz Biothechnology, Santa Cruz, CA, USA), anti-smooth muscle myosin Sclerosing adenosis (n ¼ 6) Myoepithelial 6/6 (100) 6/6 (100) 6/6 (100
The positive cases in this table showed a score Z2. a Low intensity of staining.
heavy chain (clone SMMS-1; ready-to-use, BioGenex, San Ramon, CA, USA), and anti-p63 (clone 4A4; dilution 1:50; NeoMarkers, Fremont, CA, USA). Negative controls were obtained by omitting the primary antibodies. Benign breast parenchyma adjacent to the lesion served as an internal positive control.
Scoring
The 
Results
The results of immunostainings for p75 NTR , p63 and myosin are summarized in Tables 1 and 2 .
p75 NTR Expression in Myoepithelial Cells
Myoepithelial cells of the normal mammary ducts and acini were consistently positive for p75 NTR ( Figure 1 ). p75 NTR immunoreactivity was observed on the cell membrane and in some cases in the cytoplasm. p75
NTR was always found in the myoepithelial layer of usual ductal hyperplasia, sclerosing adenosis (Figure 2a 
p75 NTR Expression in Luminal/Tumor Cells
In two of the six usual ductal hyperplasias included in this study, weak membranous p75 NTR immunoreactivity was observed in the cells in the solid areas. Ductal carcinoma in situ (Figure 2g ), noninvasive papillary carcinoma (Figure 3d) , and lobular carcinoma in situ do not show p75 NTR positivity in the luminal/tumor cells. None of the invasive lobular carcinomas, tubular carcinomas (Figure 2d ), invasive papillary carcinomas (Figure 3g) Papillary (n ¼ 6) 6/6 (100%) 0/6 (0%) 0/6 (0%) 0/6 (0%) 6/6 (100%) 0/6 (0%) 0/6 (0%) 0/6 (0%) 6/6 (100%) 0/6 (0%) 0/6 (0%) 0/6 (0%) positive stromal cells were found in the specimens with invasive carcinoma. In most of the cases, it was difficult to establish if those positive cells are fibroblasts or part of the vascular bed. A positive staining for p75 NTR was seen in the fibroblast of the expanding intralobular stroma (fibroadenomatoid change) and in the nonhyalinized stromal components of all fibroadenomas (n ¼ 6) included in our study. Despite this pattern of staining, no difficulties in the evaluation of the immunostain of myoepithelial cells were encountered.
Correlation of p75 NTR Expression with p63 and Myosin
In myoepithelial cells, the expression pattern of p75 NTR was compatible with those of p63 and myosin ( Table 1) . None of the cases with p75 NTRpositive luminal/tumor cells show immunoreactivity for myosin (Tables 1 and 2 ). Two of the three usual ductal hyperplasias with p63-positive cells in the lumen also showed p75 NTR -positive cells in the same areas. All metaplastic carcinomas included in this study expressed both p75 NTR and p63. Similar double expression was found in two invasive ductal carcinomas. Two invasive ductal carcinomas and one ductal carcinoma in situ showed focal p63 positivity in the tumor cells, but were negative for p75 NTR Two invasive ductal carcinomas with focal p75 NTR positivity did not show expression of p63. The p75 NTR -positive stromal cells in the specimens with fibroadenomatoid change and fibroadenoma were negative for p63 and myosin.
Discussion
Similarly to the previous reports, 13, 14 we found that p75 NTR is consistently expressed in the myoepithelial cells of the human mammary gland. We also showed that p75 NTR always highlighted the myoepithelial cells in the benign breast lesions (slerosing adenosis, ductal hyperplasia, intraductal papilloma) and carcinoma in situ and was absent in the majority of the invasive carcinomas. The data support the notion that p75 NTR can be used to evaluate difficult sclerosing lesions or to distinguish between in situ and invasive disease.
All metaplastic carcinomas included in our study as well as a small portion of invasive ductal carcinomas, showed expression of p75 NTR Similarly, Aragona et al, 14 who used the same monoclonal antibody on frozen sections, have found that 15% of the breast cancers included in their study are positive for p75 NTR However, using a polyclonal antibody on paraffin sections, Sakamoto et al 15 have reported that 73% of the breast carcinomas express p75 NTR in more than 15% of cancer cells. Those discrepancies might be explained with the use of different antibodies and different tissue preparation techniques. In addition, Aragona et al 14 have shown that p75 NTR expression is associated with estrogen receptor positivity and more differentiated histologic grade. This result is unexpected since the tumors that express myoepithelial/basal markers usually lack estrogen receptors and are poorly differentiated. 16, 17 Our previous study has shown that the metaplastic breast carcinomas are estrogen receptor negative and express a variety of myoepithelial/ basal markers. 18 In our current study, all metaplastic carcinomas were positive for p75 NTR which supports the prediction that p75 NTR will be expressed in the estrogen receptor negative basal-like breast carcinomas. Obviously, larger studies addressing the correlation of p75 NTR with other phenotypic characteristics of the tumors (which is not the focus of this publication) will resolve this issue. p75 NTR expression in myoepihelial cells correlates well with p63 and myosin immunoreactivity. However, the overall p75 NTR expression in breast parenchyma/tumors showed greater similarity to p63 rather than to myosin. None of the p75 NTR -positive carcinomas or the p75 NTR -positive cells in the florid usual ductal hyperplasia showed myosin expression. Discrepancy between p75 and p63 immunostains was observed in four invasive ductal carcinomas, one ductal carcinoma in situ, and one usual ductal hyperplasia. However, the immunoreactivity in these cases was focal and this inconsistency may represent a sampling artifact. Our experience showed that the membranous and cytoplasmic pattern of p75 NTR immunoreactivity was often more easily appreciated than the nuclear pattern of p63. The expression of p75 NTR on the cell membrane and in cytoplasm nicely complemented p63 immunoreactivity when a cocktail of the two antibodies was used (data not shown).
Several experimental studies have shown that under different conditions breast myoepithelial cells may change their immunophenotype. For example, Stingl et al 19 have demonstrated that, in culture conditions, mammary epithelial cells with myoepithelial features lack SMA. Similarly, other authors have reported decreased CD10 and SMA expression in continuously passaged purified human breast myoepithelial cells. 20 We have found that the myoepithelial component of adenomyoepitheliomas often does not express CD10 and/or myosin, while SMA expression often decreases. 18 All of these facts suggest that a panel containing complementary myoepithelial markers should be used when an evaluation of myoepithelial cells or tumor phenotype is required. In this respect, p75 NTR can also be included in the panel of immunohistochemical stains necessary for establishment of myoepithelial/basal origin or differentiation of breast lesions. p75 NTR immunoreactivity was noticed in the vascular adventitia, nerves, few spindle stromal cells in benign and malignant lesions. p75 NTR has been previously detected in the nerves 13, 14, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and vessels.
13,14 Although we did not observe significant p75 NTR expression in the fibroblast in normal breast stroma and in the stroma around the carcinoma, we found strong p75 NTR expression in the fibroblasts of the expanding intralobular stroma (fibroadenomatoid change). In addition to the myoepithelial positivity, further immunohistochemical staining performed on six fibroadenomas revealed similar strong stromal p75 NTR expression. These findings suggest that neurotrophins play a role in the development of mammary fibroepithelial tumors. Despite the nonepithelial expression of p75 NTR no difficulties were encountered during the evaluation of the immunostain of myoepithelial cells.
In summary, p75 neurotrophin receptor is a useful marker for breast myoepithelial cells and can be used to rule out invasive disease or to evaluate difficult sclerosing lesions. p75
NTR has a pattern of expression in breast parenchyma/tumors more similar to that of p63 than to that of the myosin heavy chain. The membranous and cytoplasmic expression of p75 NTR was often more easily appreciated than the nuclear expression of p63. p75 NTR expression in the stroma of fibroadenoma suggests a role of neurotrophins in the development of fibroepithelial breast tumors and some of the breast carcinomas.
